NCT01729091View on ClinicalTrials.gov

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 10, 2013

Primary Completion Date

June 25, 2024

Study Completion Date

June 25, 2024

Conditions

Plasma Cell LeukemiaPlasma Cell Myeloma

Interventions

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous stem cell transplant

BIOLOGICAL

Elotuzumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

DRUG

Melphalan

Given IV

BIOLOGICAL

Natural Killer Cell Therapy

Given IV

BIOLOGICAL

Umbilical Cord Blood-Derived Lymphocyte Therapy

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01729091 - Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter